Sights for Sore Eyes and Disappointments in Psychopharmacology
TLDR The document concludes that there is hope for future psychopharmacology research despite challenges in treating schizophrenia.
The document from June 2014 discusses the role of chance in the discovery of drugs, including the use of minoxidil for hair growth and MAOIs for depression, while also acknowledging the setbacks such as drugs being withdrawn for severe side effects. It highlights the discontinued bitopertin study for schizophrenia due to lack of efficacy and the difficulties in treating the negative symptoms of the disease. The article references a study by Hallak et al. that showed promise in treating schizophrenia with sodium nitroprusside, but notes the study's small sample size as a limitation. The document concludes with a hopeful outlook on ongoing research in psychopharmacology, despite the challenges and unmet needs in schizophrenia treatment.